Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.37 USD | -4.04% | +4.23% | -81.03% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
Evolution of the average Target Price on Agile Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Agile Therapeutics, Inc.
Maxim | |
HC Wainwright | |
Oppenheimer | |
RBC Capital Markets |
EPS Revisions
- Stock Market
- Equities
- AGRX Stock
- Consensus Agile Therapeutics, Inc.